Table 4. Adverse events according to... | American Society of Hematology

Table 4.

Adverse events according to risk groups and stages

	Risk group, no.									Stage, no.
	All	R1	R2	R3	R4	I	II	III	IV CNS^-	IV CNS⁺	B-AL CNS^-	B-AL CNS⁺
No. patients	505	48	233	82	142	53	119	221	16	17	56	23
Early death of tumor lysis syndrome,	1	0	0	0	1	0	0	0	0	0	1	0
Death unrelated to tumor	10	0	1	2	7	0	0	4	1	0	4	1
Tumor failure	39	1 §	10	9	19	16	0	22	0	4	5	7
Late event^*	1	0	0	1	0	0	0	0	1	0	0	0
Second malignancy†	3	1	2	0	0	0	1	2	0	0	0	0
Lost to follow-up‡	14	0	11	2	1	2	3	8	0	0	0	1

	Risk group, no.									Stage, no.
	All	R1	R2	R3	R4	I	II	III	IV CNS^-	IV CNS⁺	B-AL CNS^-	B-AL CNS⁺
No. patients	505	48	233	82	142	53	119	221	16	17	56	23
Early death of tumor lysis syndrome,	1	0	0	0	1	0	0	0	0	0	1	0
Death unrelated to tumor	10	0	1	2	7	0	0	4	1	0	4	1
Tumor failure	39	1 §	10	9	19	16	0	22	0	4	5	7
Late event^*	1	0	0	1	0	0	0	0	1	0	0	0
Second malignancy†	3	1	2	0	0	0	1	2	0	0	0	0
Lost to follow-up‡	14	0	11	2	1	2	3	8	0	0	0	1

Not possible to perform a successful molecular study on clonal differences between the first and the second malignant growths.

†

Secondary NHL in 2 cases, malignant melanoma in 1 patient.

‡

After event-free follow-up duration of 0.4 to 5.4 years (median, 2.75 years).

Primary in parailiac nodes, combined local and bone marrow relapse 3 months after completion of front-line therapy. The patient is in complete second remission for 34 months following salvage therapy including megadose chemotherapy with autologous stem cell rescue.

View Large

This Feature Is Available To Subscribers Only